Supernus Pharmaceuticals EBIT Margin 2011-2023 | SUPN
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Supernus Pharmaceuticals (SUPN) over the last 10 years. The current EBIT profit margin for Supernus Pharmaceuticals as of December 31, 2023 is .
| Supernus Pharmaceuticals EBIT Margin Historical Data |
| Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
| 2023-12-31 |
$0.61B |
$-0.01B |
-0.99% |
| 2023-09-30 |
$0.61B |
$0.03B |
4.75% |
| 2023-06-30 |
$0.63B |
$0.02B |
3.00% |
| 2023-03-31 |
$0.67B |
$0.05B |
7.19% |
| 2022-12-31 |
$0.67B |
$0.05B |
6.75% |
| 2022-09-30 |
$0.66B |
$0.02B |
2.58% |
| 2022-06-30 |
$0.63B |
$0.05B |
8.25% |
| 2022-03-31 |
$0.60B |
$0.08B |
12.48% |
| 2021-12-31 |
$0.58B |
$0.09B |
14.85% |
| 2021-09-30 |
$0.56B |
$0.12B |
21.81% |
| 2021-06-30 |
$0.57B |
$0.15B |
25.57% |
| 2021-03-31 |
$0.56B |
$0.16B |
28.37% |
| 2020-12-31 |
$0.52B |
$0.17B |
33.40% |
| 2020-09-30 |
$0.48B |
$0.17B |
36.06% |
| 2020-06-30 |
$0.42B |
$0.16B |
36.79% |
| 2020-03-31 |
$0.40B |
$0.15B |
38.06% |
| 2019-12-31 |
$0.39B |
$0.15B |
38.01% |
| 2019-09-30 |
$0.41B |
$0.15B |
36.27% |
| 2019-06-30 |
$0.41B |
$0.15B |
35.45% |
| 2019-03-31 |
$0.40B |
$0.14B |
34.16% |
| 2018-12-31 |
$0.41B |
$0.14B |
35.21% |
| 2018-09-30 |
$0.38B |
$0.14B |
36.22% |
| 2018-06-30 |
$0.36B |
$0.12B |
34.36% |
| 2018-03-31 |
$0.33B |
$0.11B |
33.83% |
| 2017-12-31 |
$0.30B |
$0.10B |
32.78% |
| 2017-09-30 |
$0.28B |
$0.08B |
29.35% |
| 2017-06-30 |
$0.25B |
$0.08B |
31.23% |
| 2017-03-31 |
$0.23B |
$0.07B |
28.38% |
| 2016-12-31 |
$0.22B |
$0.05B |
25.12% |
| 2016-09-30 |
$0.20B |
$0.05B |
23.35% |
| 2016-06-30 |
$0.18B |
$0.03B |
17.32% |
| 2016-03-31 |
$0.16B |
$0.02B |
14.11% |
| 2015-12-31 |
$0.15B |
$0.02B |
14.19% |
| 2015-09-30 |
$0.14B |
$0.02B |
13.33% |
| 2015-06-30 |
$0.12B |
$0.01B |
10.08% |
| 2015-03-31 |
$0.11B |
$0.01B |
10.62% |
| 2014-12-31 |
$0.09B |
$-0.00B |
-5.38% |
| 2014-09-30 |
$0.07B |
$-0.02B |
-29.17% |
| 2014-06-30 |
$0.05B |
$-0.04B |
-74.00% |
| 2014-03-31 |
$0.02B |
$-0.06B |
-280.00% |
| 2013-12-31 |
$0.01B |
$-0.06B |
-554.55% |
| 2013-09-30 |
$0.00B |
$-0.06B |
-3150.00% |
| 2013-06-30 |
$0.00B |
$-0.06B |
-5800.00% |
| 2013-03-31 |
$0.00B |
$-0.05B |
-5200.00% |
| 2012-12-31 |
$0.00B |
$-0.04B |
-4200.00% |
| 2012-09-30 |
$0.00B |
$-0.04B |
inf% |
| 2012-06-30 |
$0.00B |
$-0.04B |
inf% |
| 2012-03-31 |
$0.00B |
$-0.04B |
-3600.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.655B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
